Patents Examined by Erin M Bowers
-
Patent number: 11946083Abstract: The present invention relates to the production of capsaicinoid compounds including Capsaicin and Nonivamide via microbial fermentation.Type: GrantFiled: August 24, 2022Date of Patent: April 2, 2024Assignee: Conagen Inc.Inventors: Hui Chen, Xiaodan Yu, LanLan Zhou, Hongxue Wang, Min Wang
-
Patent number: 11938245Abstract: Cartilage fibers and implants made therefrom are disclosed, with and without cartilage particles. Methods for making the cartilage fibers and the implants containing them are also disclosed. The implants may be pre-shaped, may be reshapable and, when implanted in a cartilage defect, the implants have good shape retention, little swelling, completely fill the cartilage defect and resist migration from the defect upon irrigation.Type: GrantFiled: March 31, 2021Date of Patent: March 26, 2024Assignee: Musculoskeletal Transplant FoundationInventors: Michael A. Nasert, Florence Stoffel, Paul R. Williams, Alex Callahan
-
Patent number: 11931383Abstract: The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.Type: GrantFiled: August 17, 2021Date of Patent: March 19, 2024Assignee: ProKidneyInventors: Deepak Jain, Timothy A. Bertram
-
Patent number: 11879149Abstract: There is provided a novel quantification method for quantifying a concentration of EAP, which is a biomarker of depression, an enzyme for quantitation, a composition for quantitation, a kit for quantitation or a sensor for quantitation. There is provided a quantification method of ethanolamine phosphate by adding oxidoreductase to a sample containing ethanolamine phosphate. A mediator may be reduced by adding the oxidoreductase, and the reduced mediator may be reacted with a reagent to determine a concentration of ethanolamine phosphate. In addition, hydrogen peroxide produced by adding the oxidase as the oxidoreductase may be reacted with a reagent to determine a concentration of the ethanolamine phosphate.Type: GrantFiled: June 11, 2021Date of Patent: January 23, 2024Assignee: KIKKOMAN CORPORATIONInventors: Atsushi Ichiyanagi, Yosuke Masakari, Haruka Hiraguchi
-
Patent number: 11878044Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.Type: GrantFiled: February 17, 2021Date of Patent: January 23, 2024Assignee: NoNO Inc.Inventor: Michael Tymianski
-
Patent number: 11857608Abstract: Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 ?g/kg to about 10.0 ?g/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.Type: GrantFiled: March 9, 2018Date of Patent: January 2, 2024Assignee: DiaMedica Inc.Inventors: Rick Pauls, Todd Verdoorn
-
Patent number: 11841362Abstract: The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject.Type: GrantFiled: December 22, 2021Date of Patent: December 12, 2023Assignee: Centogene GmbHInventors: Arndt Rolfs, Hermann Mascher
-
Patent number: 11821905Abstract: A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development.Type: GrantFiled: September 8, 2021Date of Patent: November 21, 2023Assignee: ARTEREZ, INC.Inventor: Josefino B. Tunac
-
Patent number: 11819524Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures.Type: GrantFiled: November 25, 2019Date of Patent: November 21, 2023Assignee: Solarea Bio, Inc.Inventors: Gerardo V. Toledo, Eric Michael Schott, Maria Juliana Soto-Giron, Jinwoo Kim, Julie E. Button
-
Patent number: 11806443Abstract: Cartilage fibers and implants made therefrom are disclosed, with and without cartilage particles. Methods for making the cartilage fibers and the implants containing them are also disclosed. The implants may be pre-shaped, may be reshapable and, when implanted in a cartilage defect, the implants have good shape retention, little swelling, completely fill the cartilage defect and resist migration from the defect upon irrigation.Type: GrantFiled: May 21, 2021Date of Patent: November 7, 2023Assignee: Musculoskeletal Transplant FoundationInventors: Michael A. Nasert, Florence Stoffel, Paul R. Williams, Alex Callahan
-
Patent number: 11795493Abstract: A microfluidic apparatus, method, and associated applications utilize and apply to a formalin-fixed paraffin-embedded (FFPE) tissue sample and performing a liquid-liquid extraction to remove the paraffin from the tissue sample prior to a nucleic acid purification step. A microfluidic device includes a dedicated liquid-liquid extraction process vessel, a nucleic acid purification process component, and a nucleic acid amplification reactor. A liquid-liquid extraction and nucleic acid purification kit includes a microfluidic device capable of performing both a liquid-liquid extraction process and a nucleic acid purification process, including a dedicated liquid-liquid extraction process vessel, an immiscible liquid or a precursor phase thereof disposed in the vessel, a nucleic acid purification process component, a nucleic acid amplification reactor fluidically, and a supply of reagents suitable to enable the liquid-liquid extraction process and the nucleic acid purification process.Type: GrantFiled: November 9, 2020Date of Patent: October 24, 2023Assignee: Rheonix, Inc.Inventor: Peng Zhou
-
Patent number: 11793203Abstract: Compositions and methods of use thereof for delivering an insecticide to water-borne insect larvae are provided. Whereas individual cells of the insecticidal bacteria such as Bacillus thuringiensis israelensis (Bti), are effective in killing insect larvae when ingested by same, their use in aqueous environments is restricted by the time that the bacterial cells remain suspended in water and hence available for ingestion by the larvae. To increase the time that the insecticidal bacteria remain in suspension, it has now been found advantageous to mix bacterial suspensions with nanoparticles comprising carbon that attach to the external surface of the cells.Type: GrantFiled: January 20, 2017Date of Patent: October 24, 2023Assignee: The UAB Research FoundationInventors: Stephen A. Watts, Andrei V. Stanishevsky, Mickie L. Powell, Robert Novak
-
Patent number: 11796534Abstract: Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.Type: GrantFiled: April 13, 2018Date of Patent: October 24, 2023Assignee: Juno Therapeutics, Inc.Inventors: Paul Ken Kodama, Tom Kowski, Mima Mujacic, Kenneth Mayo Prentice
-
Patent number: 11788112Abstract: The present disclosure provides, among other things, methods and compositions for diagnosing and treating stress-induced injuries, hypoxia in particular. The present invention is based, in part, on the novel discovery that a metabolite, L-2-hydroxyglutarate, and certain enzymes and substrates regulating its metabolism, mediate stress-induced cellular mechanisms. In some embodiments, provided methods and compositions are used to diagnose and treat diseases with hypoxia-induced injuries. In some embodiments, provided methods and compositions are used to modulate cell pluripotency or differentiation in vivo or in vitro.Type: GrantFiled: June 25, 2019Date of Patent: October 17, 2023Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Andrew M. Intlekofer, Craig B. Thompson
-
Lactic acid bacteria composition for reducing fat and promoting exercise performance and use thereof
Patent number: 11779615Abstract: The present invention provides a lactic acid bacteria composition, which comprises: a Lactobacillus plantarum PL-02 strain, a Lactobacillus acidophilusTYCA06 strain, a Lactobacillus casei CS-773 strain, and a physiologically acceptable excipient, diluent, or carrier. All of the strains are deposited at the China General Microbiological Culture Collection Center.Type: GrantFiled: July 19, 2021Date of Patent: October 10, 2023Assignee: GLAC BIOTECH CO., LTDInventors: Chi-Chang Huang, Mon-Chien Lee, Yi-Ju Hsu, Hsieh-Hsun Ho, Yi-Wei Kuo, Wen-Yang Lin, Jia-Hung Lin, Chi-Huei Lin -
Patent number: 11771114Abstract: The present invention describes methods to produce a synthetic or semi-synthetic cysteine synthase/PLP-dependent decarboxylase (sCs/PLP-DC). More particularly, the invention relates to genetic modification of organisms including eukaryotes and prokaryotes to express a functional sCs/PLP-DC. The invention includes methods to produce taurine in organisms that contain native or heterologous (transgenic) taurine biosynthetic pathways or cells that have taurine by enrichment. The invention also relates to methods to increase taurine levels in the cells and to use the said cells or extracts or purifications from the cells that contain the invention to produce plant growth enhancers, food, animal feed, aquafeed, food or drink supplements, animal-feed supplements, dietary supplements, health supplements or taurine.Type: GrantFiled: November 13, 2017Date of Patent: October 3, 2023Assignee: PLANT SENSORY SYSTEMS, LLCInventor: Frank J. Turano
-
Patent number: 11771081Abstract: A repaired ex vivo organ suitable for transplantation in a human, said repaired ex vivo organ having undergone ex vivo organ perfusion for a maintenance period, wherein said organ had been assessed as being unsuitable for transplantation into a human before the maintenance period and was determined to be suitable for transplantation after the maintenance period.Type: GrantFiled: July 11, 2022Date of Patent: October 3, 2023Inventors: Shaf Keshavjee, Marcelo Cypel
-
Patent number: 11767522Abstract: Provided is a composition for preserving cell-free nucleic acids and/or cells in a biological sample and methods for use thereof. The composition comprises at least one volume excluding polymer, at least one osmotic agent and at least one enzyme inhibitor. The composition optionally further comprises at least one metabolic inhibitor. Further, provided is a kit comprising the composition, preferably in a blood collection tube, or the components of the composition.Type: GrantFiled: May 16, 2017Date of Patent: September 26, 2023Assignee: Norgen Biotek Corp.Inventors: Taha Alexander Haj-Ahmad, Yousef Haj-Ahmad
-
Patent number: 11708402Abstract: This invention reveals the potential applications of modified porcine plasma fibronectin that could be applied as a safe material for clinical wound healing and tissue repair. In order to seek safe sources of plasma fibronectin for practical consideration in wound dressing, this invention isolated and modified fibronectin from porcine plasma and demonstrated that modified porcine plasma fibronectin has similar ability as homo plasma fibronectin being as a suitable substrate for stimulation of cell adhesion and directed cell migration. The present invention also reveals a material and a pharmaceutical composition enhance wound healing.Type: GrantFiled: January 31, 2020Date of Patent: July 25, 2023Assignee: National Yang Ming Chiao Tung UniversityInventor: Jean-Cheng Kuo
-
Patent number: 11702623Abstract: The present invention relates to a device and a method for building a 3D object by mixing a bioink solution, a buffer solution capable of inducing gelation of the bioink solution and a dispersion containing micro and/or nanoparticles, and ejecting the formed hydrogel out of a nozzle. The present invention further relates to a method of obtaining a hydrogel.Type: GrantFiled: March 29, 2018Date of Patent: July 18, 2023Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Charlotte A. E. Hauser, Sakandar Rauf